Company Overview

Elutia Inc. is a U.S.-based medical technology company operating in the biologics, implantable medical devices, and drug-eluting biomaterials industries. The company develops and commercializes biologic and polymer-based products designed to improve outcomes in cardiac, vascular, orthopedic, and reconstructive surgery procedures. Elutia’s core offerings focus on infection prevention, tissue regeneration, and structural support for implanted medical devices, serving hospitals, surgeons, and healthcare systems.

The company’s primary revenue drivers are biologic envelopes, extracellular matrix (ECM) products, and antibiotic-eluting implants used in cardiovascular and soft tissue procedures. Elutia is positioned as a specialized supplier of differentiated biologic materials that integrate with existing surgical workflows. The company traces its current form to a strategic merger with Aziyo Biologics, which significantly expanded its commercial product portfolio and U.S. market presence. The corporate rebranding to Elutia Inc. reflected a strategic emphasis on therapeutic biomaterials and implant protection technologies.

Business Operations

Elutia generates revenue through the sale of proprietary implantable biologic products and related surgical solutions. Its major operating focus areas include cardiovascular protection products, soft tissue reconstruction, and infection mitigation technologies. Key products include biologic envelopes and ECM-derived implants that are sold directly to hospitals and through medical device distribution channels, primarily in the United States.

Operations are concentrated in the U.S., with manufacturing, product development, and commercial activities supported by controlled biologic processing technologies and intellectual property portfolios acquired through prior transactions. The company operates primarily through its wholly owned subsidiaries formed through the Aziyo Biologics transaction, which brought established products, supplier relationships, and hospital system penetration. Data on additional joint ventures or material third-party manufacturing dependencies is inconclusive based on available public sources.

Strategic Position & Investments

Elutia’s strategy centers on expanding adoption of biologic implant protection solutions in high-growth surgical markets, particularly cardiac rhythm management and reconstructive surgery. Growth initiatives include deeper penetration of existing hospital customers, surgeon education, and selective product innovation focused on antibiotic-eluting and regenerative biomaterials.

A defining strategic investment was the acquisition of Aziyo Biologics, which added FDA-cleared products such as CanGaroo ECM envelopes and significantly increased Elutia’s commercial scale. The company continues to invest in next-generation biomaterials that combine structural support with localized drug delivery. Public disclosures indicate ongoing evaluation of adjacent surgical applications, though details on future acquisitions or pipeline assets beyond current platforms are limited, and data is inconclusive regarding near-term M&A plans.

Geographic Footprint

Elutia is headquartered in the United States and derives the majority of its revenue from the North American healthcare market. Its products are sold primarily to U.S. hospitals and surgical centers, where reimbursement frameworks and established clinical adoption support its commercial strategy.

International exposure is limited but includes select distribution arrangements in Europe and other developed healthcare markets. The company does not report significant manufacturing or standalone operational hubs outside the U.S., and its global footprint is best characterized as U.S.-centric with targeted international reach rather than broad multinational operations.

Leadership & Governance

Elutia is led by an executive team with experience in medical devices, biologics, and healthcare commercialization. Leadership emphasizes disciplined capital allocation, clinical validation, and scalable commercialization of differentiated biomaterials.

• R. Scott Rader – President & Chief Executive Officer
• Nicholas Colacchio – Chief Financial Officer
• David Green – Chief Commercial Officer
• Kevin R. Johnson – Chief Operating Officer

While executive roles and titles are disclosed in public filings, some historical leadership details and committee-level governance responsibilities are not consistently reported across sources; certain governance specifics are therefore inconclusive based on available public information.